RxDoctor Payments Data

William Athans, OD

Optometrist · Pinehurst, NCNPI 1417902156

Payments from drug & device makers

What this record shows

17 manufacturers reported payments, led by Coopervision Inc. at 47.6% of the total.

$3,499in general payments, 2019–2025

Across 60 payments — averaging $58.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$2K
  • Alcon$852
  • Bausch & Lomb Americas Inc.$274
  • Biotissue Holdings Inc.$132
  • AbbVie$84
  • Johnson & Johnson Vision Care, Inc.$78
  • plus $411 from 11 others
$4,410in research payments, 2019–2025

Across 117 payments — averaging $37.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$4K

What the payments were for

  • Speaking & faculty fees$1,56645%
  • Food & beverage$1,93355%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,499 in reported general payments places this provider in the 80th percentile of 1,326 optometrist providers in North Carolina.

See all optometrist providers in North Carolina →

Medicare billing

Part B allowed, 2024
$167,839
Medicare patients
957
Services billed
1,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost86$42,548
RestasisCyclosporine23$20,263
Alphagan PBrimonidine Tartrate33$11,242
CombiganBrimonidine Tartrate/Timolol16$7,057
Brimonidine Tartrate49$6,992
Tobramycin-DexamethasoneTobramycin/Dexamethasone83$6,314
SimbrinzaBrinzolamide/Brimonidine Tart15$4,914
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$3,598
Travoprost19$3,185
Fluorometholone17$2,382
Latanoprost152$2,043
Timolol Maleate55$1,940
Prednisolone Acetate35$1,595
Tobramycin40$258
Ketorolac Tromethamine12$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$84$81,110158 claims
AlconSimbrinza$852$4,91415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 optometrist providers in North Carolina.

Other optometrist in Pinehurst

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →